The estimated Net Worth of Sunil Bhonsle is at least $763 Mille dollars as of 18 July 2016. Sunil Bhonsle owns over 10,000 units of Titan Pharmaceuticals, (de) stock worth over $763,304 and over the last 9 years Sunil sold TTNP stock worth over $0.
Sunil has made over 3 trades of the Titan Pharmaceuticals, (de) stock since 2016, according to the Form 4 filled with the SEC. Most recently Sunil bought 10,000 units of TTNP stock worth $49,600 on 18 July 2016.
The largest trade Sunil's ever made was buying 11,763 units of Titan Pharmaceuticals, (de) stock on 22 February 2016 worth over $41,876. On average, Sunil trades about 3,943 units every 26 days since 2016. As of 18 July 2016 Sunil still owns at least 135,578 units of Titan Pharmaceuticals, (de) stock.
You can see the complete history of Sunil Bhonsle stock trades at the bottom of the page.
Sunil's mailing address filed with the SEC is 400 OYSTER POINT BLVD., SUITE 505, , S SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Titan Pharmaceuticals, (de) have traded over $4,610,001 worth of Titan Pharmaceuticals, (de) stock and bought 3,252,657 units worth $2,558,794 . The most active insiders traders include David E.Activist Investing ..., James R Mcnab e Marc Rubin. On average, Titan Pharmaceuticals, (de) executives and independent directors trade stock every 204 days with the average trade being worth of $2,815,253. The most recent stock trade was executed by David E.Activist Investing ... on 21 June 2023, trading 3,747,968 units of TTNP stock currently worth $4,610,001.
titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Titan Pharmaceuticals, (de) executives and other stock owners filed with the SEC include: